Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JANET L DITTUS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1104817667
CMS profile
321812
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$58.91

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $35.20 1
Food and Beverage $23.71 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
ASCEND THERAPEUTICS US, LLC $35.20 1
PFIZER INC. $23.71 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JANET L DITTUS

NPI 1104817667 · CMS profile ID 321812

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JANET L DITTUS, NPI 1104817667, CMS profile ID 321812. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JANET L DITTUS, NPI 1104817667, CMS profile ID 321812, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104817667?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $58.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $11.5804/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743176389 CMS
ASCEND THERAPEUTICS US, LLC $35.2002/13/2020 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742114409 CMS
PFIZER INC. $12.1301/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743158617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $239.38 16
PY2020 $58.91 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $76,960.26 59
PY2024 Principal investigator $125,208.78 84
PY2023 Principal investigator $164,586.56 110
PY2022 Principal investigator $206,862.26 97
PY2021 Principal investigator $276,121.42 137
PY2020 Principal investigator $399,361.17 89
PY2019 Principal investigator $337,852.09 56

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

137 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,278.15 12/31/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792489441
Principal investigator 1 ABBVIE INC. $11,670.63 12/23/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792488165
Principal investigator 1 ABBVIE INC. $90.00 12/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792487197
Principal investigator 1 ABBVIE INC. $100.94 12/14/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792486951
Principal investigator 1 ABBVIE INC. $100.00 12/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792485991
Principal investigator 1 ABBVIE INC. $601.25 12/02/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792484707
Principal investigator 1 ABBVIE INC. $4,245.01 12/02/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792485159
Principal investigator 1 ABBVIE INC. $70.32 11/23/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792483981
Principal investigator 1 ABBVIE INC. $1,193.75 11/18/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792483539
Principal investigator 1 ABBVIE INC. $69.95 11/18/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792483541
Principal investigator 1 ABBVIE INC. $5,605.00 11/18/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792483543
Principal investigator 1 ABBVIE INC. $1,193.75 11/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792481679
Principal investigator 1 ABBVIE INC. $90.00 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792481073
Principal investigator 1 ABBVIE INC. $11.10 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792481075
Principal investigator 1 ABBVIE INC. $346.25 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792481077
Principal investigator 1 ABBVIE INC. $528.75 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792481317
Principal investigator 1 ABBVIE INC. $100.00 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792481319
Principal investigator 1 ABBVIE INC. $7,363.17 11/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792481321
Principal investigator 1 ABBVIE INC. $69.95 11/03/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792480875
Principal investigator 1 ABBVIE INC. $100.00 11/03/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792480877
Principal investigator 1 ABBVIE INC. $23.12 10/28/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792480549
Principal investigator 1 ABBVIE INC. $580.00 10/28/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792480551
Principal investigator 1 ABBVIE INC. $3,575.63 10/21/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792480091
Principal investigator 1 ABBVIE INC. $69.95 10/14/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792478961
Principal investigator 1 ABBVIE INC. $10,426.88 10/14/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792478963
Principal investigator 1 ABBVIE INC. $69.95 10/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792477927
Principal investigator 1 ABBVIE INC. $100.00 10/01/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792477247
Principal investigator 1 ABBVIE INC. $3,055.02 09/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792476921
Principal investigator 1 ABBVIE INC. $3,575.63 09/23/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792476105
Principal investigator 1 ABBVIE INC. $20,434.39 09/15/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792475523
Principal investigator 1 ABBVIE INC. $60.63 09/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792474661
Principal investigator 1 ABBVIE INC. $10,130.68 09/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792475015
Principal investigator 1 ABBVIE INC. $90.00 09/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792474159
Principal investigator 1 ABBVIE INC. $59.17 09/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792474105
Principal investigator 1 ABBVIE INC. $52.25 08/31/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792473537
Principal investigator 1 ABBVIE INC. $3,575.63 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472807
Principal investigator 1 ABBVIE INC. $2,406.88 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472809
Principal investigator 1 ABBVIE INC. $3,575.63 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472811
Principal investigator 1 ABBVIE INC. $2,406.88 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472813
Principal investigator 1 ABBVIE INC. $90.00 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472815
Principal investigator 1 ABBVIE INC. $90.00 08/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792472817
Principal investigator 1 ABBVIE INC. $1,000.00 08/18/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792472269
Principal investigator 1 ABBVIE INC. $4,176.88 08/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792471949
Principal investigator 1 ABBVIE INC. $90.00 08/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792471951
Principal investigator 1 ABBVIE INC. $358.75 08/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792472051
Principal investigator 1 ABBVIE INC. $295.00 08/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792472053
Principal investigator 1 ABBVIE INC. $295.00 08/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792472055
Principal investigator 1 ABBVIE INC. $100.00 08/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792471455
Principal investigator 1 ABBVIE INC. $8,395.63 07/29/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792469027
Principal investigator 1 ABBVIE INC. $64.09 07/29/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792470309
Principal investigator 1 ABBVIE INC. $1,718.75 07/27/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792468641
Principal investigator 1 ABBVIE INC. $11.02 07/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792468359
Principal investigator 1 ABBVIE INC. $2,743.13 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467941
Principal investigator 1 ABBVIE INC. $109.50 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467943
Principal investigator 1 ABBVIE INC. $68.07 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467945
Principal investigator 1 ABBVIE INC. $59.13 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467947
Principal investigator 1 ABBVIE INC. $3,575.63 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467949
Principal investigator 1 ABBVIE INC. $3,575.63 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467951
Principal investigator 1 ABBVIE INC. $90.00 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467953
Principal investigator 1 ABBVIE INC. $2,406.88 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467955
Principal investigator 1 ABBVIE INC. $30.60 07/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467957
Principal investigator 1 ABBVIE INC. $7.00 07/15/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467805
Principal investigator 1 ABBVIE INC. $54.80 07/15/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467807
Principal investigator 1 ABBVIE INC. $3,575.63 07/13/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467427
Principal investigator 1 ABBVIE INC. $3,575.63 07/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792467281
Principal investigator 1 ABBVIE INC. $60.00 07/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467325
Principal investigator 1 ABBVIE INC. $358.75 07/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467217
Principal investigator 1 ABBVIE INC. $54.80 07/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467219
Principal investigator 1 ABBVIE INC. $15,520.03 07/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792467221
Principal investigator 1 ABBVIE INC. $516.13 07/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792466685
Principal investigator 1 ABBVIE INC. $3,598.76 07/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792466735
Principal investigator 1 ABBVIE INC. $1,787.50 07/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792466737
Principal investigator 1 ABBVIE INC. $100.00 06/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792464541
Principal investigator 1 ABBVIE INC. $580.00 06/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792464543
Principal investigator 1 ABBVIE INC. $10,550.01 06/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792464545
Principal investigator 1 ABBVIE INC. $3,575.63 06/24/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792463915
Principal investigator 1 ABBVIE INC. $90.00 06/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792463653
Principal investigator 1 ABBVIE INC. $54.28 06/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792463257
Principal investigator 1 ABBVIE INC. $580.00 06/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792463259
Principal investigator 1 ABBVIE INC. $1,435.00 06/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792463339
Principal investigator 1 ABBVIE INC. $252.50 06/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792463341
Principal investigator 1 ABBVIE INC. $100.00 06/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792463343
Principal investigator 1 ABBVIE INC. $7.20 06/10/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792462835
Principal investigator 1 ABBVIE INC. $300.00 06/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792462761
Principal investigator 1 ABBVIE INC. $5,567.54 06/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792462353
Principal investigator 1 ABBVIE INC. $5,000.00 06/03/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792461913
Principal investigator 1 ABBVIE INC. $2,752.50 06/03/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792461915
Principal investigator 1 ABBVIE INC. $358.75 05/27/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792460737
Principal investigator 1 ABBVIE INC. $656.25 05/27/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792460739
Principal investigator 1 ABBVIE INC. $4,900.66 05/27/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792460741
Principal investigator 1 ABBVIE INC. $308.00 05/26/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792459719
Principal investigator 1 ABBVIE INC. $90.00 05/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792458559
Principal investigator 1 ABBVIE INC. $7.65 05/13/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792457015
Principal investigator 1 ABBVIE INC. $19.94 05/13/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792457531
Principal investigator 1 ABBVIE INC. $9.91 05/06/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792455137
Principal investigator 1 ABBVIE INC. $2,884.28 04/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792451745
Principal investigator 1 ABBVIE INC. $2,406.88 04/30/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792451751
Principal investigator 1 ABBVIE INC. $580.00 04/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792446583
Principal investigator 1 ABBVIE INC. $580.00 04/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792446587
Principal investigator 1 ABBVIE INC. $358.75 04/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792446717
Principal investigator 1 ABBVIE INC. $55.76 04/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792446723
Principal investigator 1 ABBVIE INC. $1,787.50 04/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792446245
Principal investigator 1 ABBVIE INC. $55.76 04/15/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792445163
Principal investigator 1 ABBVIE INC. $11,836.91 04/09/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792444145
Principal investigator 1 ABBVIE INC. $2,974.38 04/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792443129
Principal investigator 1 ABBVIE INC. $135.00 04/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792443409
Principal investigator 1 ABBVIE INC. $295.00 04/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792443413
Principal investigator 1 ABBVIE INC. $55.76 04/07/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792442945
Principal investigator 1 ABBVIE INC. $315.00 04/06/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792442673
Principal investigator 1 ABBVIE INC. $1,735.94 04/05/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792442287
Principal investigator 1 ABBVIE INC. $55.76 04/01/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792440619
Principal investigator 1 ABBVIE INC. $135.00 04/01/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792441129
Principal investigator 1 ABBVIE INC. $135.00 04/01/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792441135
Principal investigator 1 ABBVIE INC. $1,987.50 03/31/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792439697
Principal investigator 1 ABBVIE INC. $55.72 03/25/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792435717
Principal investigator 1 ABBVIE INC. $145.52 03/24/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792435287
Principal investigator 1 ABBVIE INC. $670.00 03/23/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792434825
Principal investigator 1 ABBVIE INC. $63.91 03/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792433745
Principal investigator 1 ABBVIE INC. $55.72 03/16/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792433627
Principal investigator 1 ABBVIE INC. $4,963.80 03/12/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792433481
Principal investigator 1 ABBVIE INC. $2,261.25 03/08/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792432175
Principal investigator 1 ABBVIE INC. $315.00 03/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792431901
Principal investigator 1 ABBVIE INC. $63.91 03/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792431987
Principal investigator 1 ABBVIE INC. $63.91 02/25/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792425605
Principal investigator 1 ABBVIE INC. $63.91 02/17/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792423917
Principal investigator 1 ABBVIE INC. $14,994.42 02/11/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792422547
Principal investigator 1 ABBVIE INC. $6,263.76 02/04/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792420245
Principal investigator 1 ABBVIE INC. $3,320.30 02/03/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 4 Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Premenopausal Women No dispute reported 06/30/2026 792419961
Principal investigator 1 ABBVIE INC. $1,202.50 01/28/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Premenopausal Women with Documented Endometriosis and Associated Moderate to Severe Pain No dispute reported 06/30/2026 792413171
Principal investigator 1 ABBVIE INC. $13,705.04 01/28/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792416031
Principal investigator 1 ABBVIE INC. $135.00 01/22/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792411259
Principal investigator 1 ABBVIE INC. $154.04 01/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792410415
Principal investigator 1 ABBVIE INC. $100.00 01/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792410421
Principal investigator 1 ABBVIE INC. $145.30 01/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792410427
Principal investigator 1 ABBVIE INC. $145.30 01/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792410433
Principal investigator 1 ABBVIE INC. $45.60 01/20/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792410438
Principal investigator 1 ABBVIE INC. $2,972.50 01/05/2021 Non-covered Recipient Entity
ACCESS CLINICAL TRIALS
A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Estradiol/Norethindrone Acetate in Subjects with Moderate to Severe Endometriosis-Associated Pain No dispute reported 06/30/2026 792407399